

4th Human Cancer Immunology Course <u>Thursday October 4, 2018</u> Institut Jules Bordet

8:15-8:30 am Welcome and Introduction M. Piccart, MD PhD - A. Awada, MD PhD, Institut Jules Bordet (IJB) – ULB

Basic Immunology

8:30-9:00 am	Innate and adaptive immune responses against tumors Sophie Lucas, MD PhD, UCL Louvain – Institut de Duve, Belgium
9:00–9:30 am	Beyond antibody production: The important role of T cells in vaccine-induced immune responses Arnaud Marchant, MD PhD, Institute for Medical Immunology, Belgium

9:30-10:00 am Coffee break

Cancer Immunology

10:00–10:30 am	How dendritic cells and macrophages affect growth and progression in human breast cancer Christophe Caux, PhD, Léon Bérard Cancer Center, Lyon, France
10:30–11:00 am	Reactive oxygen species : regulation of metabolism, immunity and cancer Dirk Brenner, MD PhD, Luxembourg Institute of Health, Luxembourg
11:00-11:30 am	Epigenetics, immunity and human cancer Francois Fuks, PhD, ULB – Cancer Research Center (U-CRC), Belgium
11:30-12:00 am	Tumor-specific neoantigens Samra Turajlic, MD, The Francis Crick Institute, London, England
12:00-12:30 am	Primary immune deficiencies and the risk of developing cancer Jutte van der Werff ten Bosch, MD PhD, UZ Brussels, Belgium
12:30-1:30 pm	Lunch

Accreditation

Thanks to our Gold Sponsors AstraZeneca, Bristol-Myers Squibb, MSD Belgium and Roche

Location: Pullman Brussels Centre Midi Place Victor Horta 1 1060 Brussels





4th Human Cancer Immunology Course <u>Thursday October 4, 2018</u> Institut Jules Bordet

Biomarker Development for Immunotherapy

- 1:30-2:00 pm The pros and cons of sample sources including blood, serum/plasma and tumor tissue (biopsy and surgical specimens) *Valentina Pomella, MSc, KUL, Belgium*
- 2:00-2:30 pm The clinical importance of immune biomarkers in immunotherapy Roberto Salgado MD PhD, Department of Pathology, GZA-ZNA, Antwerp, Belgium
- 2:30-3:00 pm A rational approach for combination therapy in human cancer using biological together with computational approaches Marie-Agnès Doucey, MD PhD, UNIL/Ludwig, Lausanne, Switzerland
- 3:00-3:30 pm Coffee Break

Immunity and Immunotherapy in specific malignancies

- 3:30-4:00 pm Checkpoint inhibitors in human hematological malignancies Willemijn Hobo, PhD, Radboud, University Medical Center, Nijmegen, The Netherlands
- 4:00-4:30 pm Chronic lymphocytic leukemia cells influence on the non-malignant immune microenvironment *Rianne van der Windt, PhD, Amsterdam University Medical Centers, The Netherlands*
- 4:30-5:00 pm Immunotherapy for pancreatic cancer Daniel Olive, MD PhD, Aix Marseille University, Marseille, France (TBC)
- 5:00-5:30 pm Oncolytic viruses and immunotherapeutics for treating hematological and solid tumors Janet Lei, PhD, University of Oxford, United Kingdom

Accreditation

Thanks to our Gold Sponsors AstraZeneca, Bristol-Myers Squibb, MSD Belgium and Roche

Location: Pullman Brussels Centre Midi Place Victor Horta 1 1060 Brussels





4th Human Cancer Immunology Course <u>Friday October 5, 2018</u> Institut Jules Bordet

Mechanisms for priming the immune system for immunotherapy

8:30-8:45 am	Pre-treatments that prepare the immune response for priming Laurence Buisseret, MD, IJB, Belgium
8:45-9:00 am	Chemotherapy and targeted therapies as priming agents François Ghiringhelli, MD PhD, Center Georges François Leclerc, Dijon, France
9:00-9:15 am	Radiation as a priming agent Alex de Caluwe, MD, IJB, Belgium
9:15-9:30 am	Epigenetic agents for priming Sandrine Aspeslagh, MD, IJB, Belgium
9:30-10:00 am	Discussion plus leader for panel discussion (all speakers) François Ghiringhelli, MD PhD, Center Georges François Leclerc, Dijon, France
10:00-10:30 am	Coffee Break

Combination immunotherapy clinical trials:

10:30-10:45 am	Chemotherapy with immunotherapy Andrea Gombos, MD, IJB, Belgium	
10:45-11:00 am	Targeted therapy with immunotherapy Gabriele Bergers, PhD, KUL, Belgium	
11:00-11:15 am	Radiation therapy with immunotherapy Evert Van Limbergen, MD PhD, MAASTRO Clinic, Maastricht, The Netherland	nds
11:15-11:30 am	Immunotherapy in clinical research and practice: Lessons learned and perspectives Ahmad Awada, MD PhD, IJB, Belgium	
11:30-12:00 pm	Panel Discussion led by Ahmad Awada, MD PhD, IJB, Belgium	
12:00-1:00 pm	Lunch Accreditatio	n

Thanks to our Gold Sponsors AstraZeneca, Bristol-Myers Squibb, MSD Belgium and Roche <u>Location:</u> Pullman Brussels Centre Midi Place Victor Horta 1 1060 Brussels





4th Human Cancer Immunology Course <u>Friday October 5, 2018</u> Institut Jules Bordet

<u>New directions in immunotherapy: rational design of immunotherapy trials through</u> <u>academic and pharmaceutical collaborations</u>

- 1:00-1:20 pm The academic viewpoint Ahmad Awada, MD PhD, IJB, Belgium
- 1:20-1:40 pm The pharma viewpoint Axel Hanauske, MD PhD, Hamburg, Germany
- 1:40-2:10 pm Discussion led by Martine Piccart, MD PhD, IJB, Belgium

Accreditation

Thanks to our Gold Sponsors AstraZeneca, Bristol-Myers Squibb, MSD Belgium and Roche <u>Location:</u> Pullman Brussels Centre Midi Place Victor Horta 1 1060 Brussels

